News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
GW Pharmaceuticals Begins Second Pivotal Phase III Trial Of MS Drug Sativex
August 9, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
GW Pharmaceuticals PLC said it has begun a second pivotal Phase III trial of Sativex as a treatment for pain associated with multiple sclerosis.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
MORE ON THIS TOPIC
Neuroscience
Roche Piles $55M Into Blood-Brain Barrier Tech With Manifold
November 3, 2025
·
1 min read
·
Annalee Armstrong
IN PARTNERSHIP WITH ELEMENT
Pharma Faces Investor Woes and Tariff Threats, Turns to AI and Collaboration for Survival
November 3, 2025
·
5 min read
·
BioSpace Insights
Huntington’s disease
FDA Does ‘About-Face’ on UniQure’s Huntington’s Gene Therapy
November 3, 2025
·
3 min read
·
Heather McKenzie
Deals
4DMT Sends Eye Disease Asset’s Asia Rights to Otsuka for $85M Upfront
October 31, 2025
·
1 min read
·
Annalee Armstrong
